BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20664585)

  • 21. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
    Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
    Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.
    Kim SY; Theunissen JW; Balibalos J; Liao-Chan S; Babcock MC; Wong T; Cairns B; Gonzalez D; van der Horst EH; Perez M; Levashova Z; Chinn L; D'Alessio JA; Flory M; Bermudez A; Jackson DY; Ha E; Monteon J; Bruhns MF; Chen G; Migone TS
    Blood Cancer J; 2015 May; 5(5):e316. PubMed ID: 26024286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
    Bourillon L; Bourgier C; Gaborit N; Garambois V; Llès E; Zampieri A; Ogier C; Jarlier M; Radosevic-Robin N; Orsetti B; Delpech H; Theillet C; Colombo PE; Azria D; Pèlegrin A; Larbouret C; Chardès T
    Int J Cancer; 2019 Oct; 145(7):1838-1851. PubMed ID: 30882895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD70, a novel target of CAR T-cell therapy for gliomas.
    Jin L; Ge H; Long Y; Yang C; Chang YE; Mu L; Sayour EJ; De Leon G; Wang QJ; Yang JC; Kubilis PS; Bao H; Xia S; Lu D; Kong Y; Hu L; Shang Y; Jiang C; Nie J; Li S; Gu Y; Sun J; Mitchell DA; Lin Z; Huang J
    Neuro Oncol; 2018 Jan; 20(1):55-65. PubMed ID: 28651374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunoconjugates, drug-armed antibodies to fight against cancer].
    Haeuw JF; Caussanel V; Beck A
    Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.
    Pes L; Koester SD; Magnusson JP; Chercheja S; Medda F; Abu Ajaj K; Rognan D; Daum S; Nollmann FI; Garcia Fernandez J; Perez Galan P; Walter HK; Warnecke A; Kratz F
    J Control Release; 2019 Feb; 296():81-92. PubMed ID: 30639692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody.
    Aung W; Tsuji AB; Sugyo A; Takashima H; Yasunaga M; Matsumura Y; Higashi T
    World J Gastroenterol; 2018 Dec; 24(48):5491-5504. PubMed ID: 30622378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin.
    Tacha D; Qi W; Zhou D; Bremer R; Cheng L
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):59-63. PubMed ID: 22595948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.
    He K; Xu J; Liang J; Jiang J; Tang M; Ye X; Zhang Z; Zhang L; Fu B; Li Y; Bai C; Zhang L; Tao W
    Mol Cancer Ther; 2019 Jun; 18(6):1104-1114. PubMed ID: 30962319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro selection of CD70 binding aptamer and its application in a biosensor design for sensitive detection of SKOV-3 ovarian cells.
    Bayat P; Taghdisi SM; Rafatpanah H; Abnous K; Ramezani M
    Talanta; 2019 Mar; 194():399-405. PubMed ID: 30609550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
    Damelin M; Bankovich A; Bernstein J; Lucas J; Chen L; Williams S; Park A; Aguilar J; Ernstoff E; Charati M; Dushin R; Aujay M; Lee C; Ramoth H; Milton M; Hampl J; Lazetic S; Pulito V; Rosfjord E; Sun Y; King L; Barletta F; Betts A; Guffroy M; Falahatpisheh H; O'Donnell CJ; Stull R; Pysz M; Escarpe P; Liu D; Foord O; Gerber HP; Sapra P; Dylla SJ
    Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.
    Sussman D; Smith LM; Anderson ME; Duniho S; Hunter JH; Kostner H; Miyamoto JB; Nesterova A; Westendorf L; Van Epps HA; Whiting N; Benjamin DR
    Mol Cancer Ther; 2014 Dec; 13(12):2991-3000. PubMed ID: 25253783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.
    Thomas LJ; Vitale L; O'Neill T; Dolnick RY; Wallace PK; Minderman H; Gergel LE; Forsberg EM; Boyer JM; Storey JR; Pilsmaker CD; Hammond RA; Widger J; Sundarapandiyan K; Crocker A; Marsh HC; Keler T
    Mol Cancer Ther; 2016 Dec; 15(12):2946-2954. PubMed ID: 27671527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.
    Shaffer DR; Savoldo B; Yi Z; Chow KK; Kakarla S; Spencer DM; Dotti G; Wu MF; Liu H; Kenney S; Gottschalk S
    Blood; 2011 Apr; 117(16):4304-14. PubMed ID: 21304103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
    Gerber HP; Kung-Sutherland M; Stone I; Morris-Tilden C; Miyamoto J; McCormick R; Alley SC; Okeley N; Hayes B; Hernandez-Ilizaliturri FJ; McDonagh CF; Carter PJ; Benjamin D; Grewal IS
    Blood; 2009 Apr; 113(18):4352-61. PubMed ID: 19147785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
    Al Sayed MF; Ruckstuhl CA; Hilmenyuk T; Claus C; Bourquin JP; Bornhauser BC; Radpour R; Riether C; Ochsenbein AF
    Blood; 2017 Jul; 130(3):297-309. PubMed ID: 28495792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
    Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Shochat D; Mountain A
    Bioconjug Chem; 2005; 16(2):354-60. PubMed ID: 15769089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97.
    Smith LM; Nesterova A; Alley SC; Torgov MY; Carter PJ
    Mol Cancer Ther; 2006 Jun; 5(6):1474-82. PubMed ID: 16818506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD70 as a therapeutic target in human malignancies.
    Grewal IS
    Expert Opin Ther Targets; 2008 Mar; 12(3):341-51. PubMed ID: 18269343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.